medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.